The main objective of present research investigation is to formulate the Moxifloxacin.HCl Fast Dissolving tablets. Moxifloxacin.HCl, a synthetic fluoroquinolone antibacterial agent, and used to treatacute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis. The Fast Dissolving tablets of Moxifloxacin.HCl were prepared employing different concentrations of Crospovidone and Croscarmellose sodium in different combinations as a Superdisintegrants by Direct Compression technique using 3 2 factorial design. The concentration of Crospovidone and Croscarmellose sodium was selected as independent variables, X1 and X2 respectively whereas, wetting time, Disintegration time, t 50% , and t 90% were selected as dependent variables. Totally nine formulations were designed and are evaluated for hardness, friability, thickness, Assay, Wetting time, Disintegration time, In-vitro drug release. From the Results concluded that all the formulation were found to be with in the Pharmacopoeial limits and the In-vitro dissolution profiles of all formulations were fitted in to different Kinetic models, the statistical parameters like intercept (a), slope (b) & regression coefficient (r) were calculated. Polynomial equations were developed for Wetting time, Disintegration time, t 50% , t 90%. Validity of developed polynomial equations were verified by designing 2 check point formulations (C1, C2). According to SUPAC guidelines the formulation (F5) containing combination of 7.5% Crospovidone and 7.5% Croscarmellose, is the most similar formulation (similarity factor f2=68.88, dissimilarity factor f1= 3.35& No significant difference, t= 0.00354) to marketed product (AVELOX-400). The selected formulation (F5) follows First order, Higuchi's kinetics, mechanism of drug release was found to be Non-Fickian Diffusion Super Case-II Transport (n= 1.902).

No abstract

Sumatriptan is a potent and selective 5-hydroxytryptamine agonist. It is an effective agent in the treatment of acute migraine attack. Sumatriptan is rapidly but incompletely absorbed following oral administration and undergoes first pass metabolism resulting in a low absolute bioavailability of 15%. The biological half-life of Sumatriptan is about 2.5 hr. The aim was to develop gastro retentive floating microbeads which improve the absolute bioavailability of Sumatriptan by avoiding the presystemic metabolism and thereby to reduce the dose frequency. Drug and polymer compatibility was studied by subjecting physical mixtures of drug and polymers to FTIR spectrophotometry, capability of floating in the gastric condition was evaluated. The beads were prepared by Ionotropic gelation method. By using Sodium alginate, hydroxyl propyl methylcellulose K 4 M and Guar gum grade in 1:1, 1:2, 1:3 ratios. The beads were evaluated for percent drug entrapment efficiency, and in vitro drug release. The in vitro drug release study of the beads was carried out in simulated gastric media by USP dissolution method.Beads formulated employing Sodium alginate alone could not sustain the drug release, whereas beads formulated with mixture of Sodium alginate and copolymers demonstrated sustained release of Sumatriptan for 12h.

The aim of this study was to study the effect of ciprofloxacin (CFX) and ibuprofen (IBF) on the in vitro metabolism of rosiglitazone (RGZ) in human liver microsomes and on the pharmacokinetics of RGZ in healthy human volunteers. A randomized, placebo controlled, 3-way crossover design oral pharmacokinetic study was done in healthy human male volunteers and in vitro metabolism studies were done in human liver microsomes to study the effect of CFX and IBF on RGZ metabolism. Each subject received orally either 8 mg of RGZ with a placebo or co-administration with either 500 mg of CFX or 400 mg of IBF. Plasma concentrations of RGZ were estimated using a validated LC-MS/MS method and the metabolism studies samples were analyzed by a reported HPLC method. There was no statistically significant difference observed in the pharmacokinetic parameters viz., AUC(0-t), AUC(O-infinity), Cmax, Tmax, Kel and t1/2 of RGZ following co-administration of either CFX or IBF. Both CFX and IBF did not affect the in vitro metabolism of RGZ in human liver microsomes.